Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint: a Multicenter, Cluster-controlled Study (PADSTONE Study)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,300
- 试验地点
- 56
- 主要终点
- The rate of progression with 4 weeks
研究概览
简要总结
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis. HBV related ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.) and confers with high risk of short-term mortality. For the treatment of ACLF patients, recent studies have explored the therapeutic efficacy of extracorporeal liver support therapies, such as albumin dialysis, plasma exchange. However, the clinical efficacy remains to be fully elucidated. Liver transplantation is the most efficient way to improve the survival of ACLF patients, especially for those suffering from three or more organ failures.
Recently, a novel extracorporeal system which is called double plasma molecular adsorption system (DPMAS) has been applied for the treatment of ACLF patients. DPMAS is an extracorporeal therapeutic procedure that combines two hemoperfusion devices. During treatment, toxic plasma is isolated and purified via perfusion through two adsorbers, after which the purified plasma is reinfused back into the patient's circulation. This technique requires no massive plasma supply and avoids the risks of plasma-related allergic reactions and pathogen transmission. DPMAS can rapidly alleviate jaundice and lower serum bilirubin levels, thereby mitigating the hepatotoxic effects induced by excessive bilirubin and bile acids. Despite the widespread clinical application of DPMAS in patients with liver failure, high-quality evidence supporting its definite clinical efficacy remains insufficient.
Accordingly, this prospective, multicenter cluster-controlled study is designed to evaluate the clinical benefits of DPMAS via validated hard clinical endpoints, including short-term mortality and disease progression, and screen out suitable candidate patients. Furthermore, biological specimens including plasma, urine and feces will be collected to characterize the molecular profiles of ACLF patients receiving DPMAS treatment through multi-omics analyses.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized patients
- •Age >18 years
- •Chronic liver disease regardless of the etiology
- •Total bilirubin ≥ 12mg/dl and INR ≥ 1.5
排除标准
- •With ≥ 3 organ failures (SOFA criteria);
- •The pregnant;
- •With severe non-hepatic disease (such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission);
- •Human immunodeficiency virus (HIV) infection without treatment;
- •Patients with unstable hemodynamics caused by infection or acute bleeding;
- •Hospital stays <48 hours;
- •Diagnosis of hepatocellular carcinoma during screening period;
- •For the DPMAS clusters: patients decline to receive DPMAS treatment alone or in combination with PE;
- •For the SOC clusters: patients plan to receive DPMAS therapy;
- •Not suitable to participate in this study judging by researchers (e.g., patients with severe advanced pancreatic tumors, hematological tumors);
- •Not sign the informed consent.
结局指标
主要结局
The rate of progression with 4 weeks
时间窗: 4 weeks
The progression of ACLF with 4 weeks
The 4-week transplant-free mortality
时间窗: 4 weeks
The 4-week transplant-free mortality
次要结局
- The transplant-free mortality within 12 weeks(12 weeks)
- The improvement of ACLF with 12 weeks(12 weeks)
研究者
Jinjun Chen
Professor
Nanfang Hospital, Southern Medical University